Fig. 8.

Activation of JNK is essential for CUDC-907-enhanced DR5 expression in breast cancer cells. a Expressions of p-ERK, p-JNK and p-p38 MAPK were measured in breast cancer cells treated with various concentrations of CUDC-907 for 24 h. b Cell pretreated with or without SP600125 (20 μM) and SB203580 (20 μM) for 1 h, and subsequently treated with or without CUDC-907 (50 nM) for 24 h. The expression of DR5 was measured by Western blotting analysis. β-Actin was used as a loading control